PacBio Announces a Private Convertible Exchange Transaction of $441 Million Principal Amount of 1.375% Convertible Senior Notes due 2030

MENLO PARK, Calif., June 26, 2023 /PRNewswire/ — Pacific Biosciences of California, Inc. (“PacBio”) (NASDAQ: PACB) today announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio’s outstanding 1.50% Convertible Senior Notes due 2028 (the “2028…

Click here to view original post